Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Other Operating Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Other Operating Expenses for 7 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $8.2 million for FY2025, 154.04% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $1.7 million at Soleno Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $3.0 million in Q1 2025, with the low at $1.7 million in Q4 2025.